Most people have never heard of spinal muscular atrophy (SMA), a rare genetic disease that affects approximately 1 in 6,000 babies born worldwide each year. Innovative research may produce treatments for patients suffering from SMA and other rare diseases.

Novartis is working to tackle the problem of counterfeit drugs, which are a threat to patient health.

In October 2013, we created a new, full-time position to lead our CR efforts. Juergen Brokatzky-Geiger, formerly Global Head of Human Resources and a member of the Executive Committee, took on this role effective in February 2014.

Dr. Matchaba describes how his unique background can help guide the company’s access-to-medicine efforts.

Cataracts are a serious but common eye condition affecting more than 20 million worldwide. A patient in Brazil tells her story.

Doyle describes the road to improving patient outcomes across Europe through the HARMONY Alliance.

Investing in innovative treatments is vital to alleviate the suffering caused by multiple sclerosis (MS).